NASDAQ:TRPX Therapix Biosciences (TRPX) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free TRPX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1250-Day Range$0.10▼$0.3252-Week Range$0.25▼$4.69Volume95,212 shsAverage Volume1.59 million shsMarket Capitalization$351,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Therapix Biosciences alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Therapix BiosciencesRead More Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> TRPX Stock News HeadlinesDecember 12, 2023 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, PredictionsAugust 23, 2023 | investing.comSagimet Biosciences Inc (SGMT)June 18, 2024 | Behind the Markets (Ad)This Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!August 1, 2023 | seekingalpha.comPBIO Pressure BioSciences, Inc.January 19, 2022 | thestreet.comCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsSee More Headlines Receive TRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapix Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/20/2018Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRPX CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3616-7055FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,510,000Free FloatN/AMarket Cap$351,000.00 OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Ascher Shmulewitz (Age 63)Chairman & Interim CEO Dr. Adi Zuloff-Shani (Age 51)Chief Technology Officer Mr. Oz Adler CPA (Age 32)Chief Financial Officer Key CompetitorsDermata TherapeuticsNASDAQ:DRMALucy Scientific DiscoveryNASDAQ:LSDIPainReformNASDAQ:PRFXQualigen TherapeuticsNASDAQ:QLGNBiodexa PharmaceuticalsNASDAQ:BDRXView All Competitors TRPX Stock Analysis - Frequently Asked Questions How were Therapix Biosciences' earnings last quarter? Therapix Biosciences Ltd. (NASDAQ:TRPX) posted its earnings results on Monday, August, 20th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.24. What other stocks do shareholders of Therapix Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Therapix Biosciences investors own include Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Tilray (TLRY), Corbus Pharmaceuticals (CRBP) and VBI Vaccines (VBIV). This page (NASDAQ:TRPX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapix Biosciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Therapix Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.